Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective (vol 43, pg S1, 2021)

被引：0

作者：

Salvino, M. A. ^{[1
,2
]}

Bonfim, C. ^{[3
]}

Calado, R. T. ^{[4
]}

Kim, H. ^{[5
]}

Bertinato, J. F. ^{[5
]}

Scheinberg, P. ^{[6
]}

机构：

[1] Univ Fed Bahia UFBA, HUPES, Salvador, BA, Brazil

[2] Hosp Sao Rafael, Inst DOr Ensino & Pesquisa IDOR, Salvador, BA, Brazil

[3] Univ Fed Parana UFPR, Dept Hematol, Blood & Marrow Transplantat Unit, Hosp Clin, Curitiba, PR, Brazil

[4] Univ Sao Paulo, FMRP, Dept Med Imaging Haematol & Clin Oncol, Curitiba, PR, Brazil

[5] Novartis Biociencias SA, Sao Paulo, SP, Brazil

[6] Beneficencia Portuguesa Sao Paulo BP, Div Hematol, Sao Paulo, SP, Brazil

来源：

HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2022年 / 44卷 / 02期

关键词：

D O I：

10.1016/j.htct.2022.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 1

页数：1

共 35 条

[31] Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediateor poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective (vol 24, pg 291, 2021)
Botrel, T. E. A.
Abadi, M. D.
Haas, L. C.
da Veiga, C. R. P.
Ferreira, de Vasconcelos D.
Jardim, D. L.
[J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 929 - 929
[32] COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS ERLOTINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR) NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Santoni, N. B.
Melo, T. G.
Aguirre, A. R.
Veiga, D. L.
Souza, C. P.
[J]. VALUE IN HEALTH, 2017, 20 (05) : A109 - A109
[33] Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective (vol 17, pg 587, 2017)
Mezquita-Raya, P.
Darba, J.
Ascanio, M.
Ramirez de Arellano, A.
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (06) : I - I
[34] Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health-Care System in China
Zhu, Chen
Xing, Xiao-xuan
Wu, Bin
Liang, Gang
Han, Gang
Lin, Cai-xia
Fang, Hong-mei
[J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
[35] PEMBROLIZUMAB VS. STANDARD OF CARE CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER WITH HIGH PD-L1 EXPRESSION LEVELS: A COST-UTILITY ANALYSIS FROM THE ONTARIO, CANADA PUBLIC PAYER PERSPECTIVE
Chu, R.
Tudor, R.
Choi, D. S.
Wong, O.
Chan, K. K. W.
Leighl, N. B.
Chan, B. C. F.
Coyte, P. C.
Rebecca, H. H.
[J]. VALUE IN HEALTH, 2023, 26 (06) : S259 - S259

← 1 2 3 4 →